Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy

J Rheumatol. 2007 Jan;34(1):238-9; author reply 239.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy
  • Aspergillus / isolation & purification
  • Bronchoalveolar Lavage
  • Cryptogenic Organizing Pneumonia / chemically induced
  • Cryptogenic Organizing Pneumonia / diagnosis
  • Cryptogenic Organizing Pneumonia / pathology
  • Humans
  • Infliximab
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Diseases, Interstitial / diagnosis
  • Lung Diseases, Interstitial / pathology
  • Mast Cells / microbiology
  • Mast Cells / pathology
  • Methotrexate / adverse effects
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Methotrexate